Quarterly report pursuant to Section 13 or 15(d)

NATURE OF BUSINESS AND ORGANIZATION (Details)

v3.23.3
NATURE OF BUSINESS AND ORGANIZATION (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Accumulated deficit   $ 210,033,882           $ 210,033,882   $ 179,499,043
Net loss   13,732,350 $ 8,221,222 $ 8,581,267 $ 7,811,322 $ 7,435,043 $ 6,139,797 30,534,839 $ 21,386,162  
Fixed asset impairment charges               0    
Uninsured cash balances   18,486,000           18,486,000   $ 19,400,000
Cancer treatment research award through the National Cancer Institute (NCI)                    
Grant amount   2,000,000.0           $ 2,000,000.0    
Grant period               3 years    
Grant received $ 1,980,000 $ 667,000           $ 1,314,000    
Leasehold improvements                    
Property and equipment useful lives   64 months           64 months    
Minimum                    
Property and equipment useful lives   3 years           3 years    
Share-based compensation expiration period               1 year    
Maximum                    
Property and equipment useful lives   10 years           10 years    
Share-based compensation expiration period               3 years